U.S. health insurer Cigna has abandoned its pursuit of a merger with rival Humana, citing an inability to reach a consensus on the acquisition’s price, according to two sources familiar with the matter. The proposed deal, which would have created a healthcare behemoth valued at over $140 billion based on market values, faced formidable antitrust scrutiny in an industry where consolidation has been closely monitored by regulators.
The discussions between Cigna and Humana, which came six years after regulatory authorities thwarted significant consolidations within the U.S. health insurance sector, concluded due to a failure to agree on financial terms, as reported by the Wall Street Journal. Despite this setback, sources suggest that a potential collaboration between the two companies remains a possibility in the future.
Following the termination of merger talks, Cigna announced its intention to repurchase an additional $10 billion worth of shares, bringing the total repurchase amount to $11.3 billion. This move resulted in a notable uptick in Cigna’s stock, with shares rising 12.1% to $290.07 in premarket trading on Monday. However, the company’s shares have experienced a 22% decline over the year, including a nearly 10% dip since reports emerged about the failed deal negotiations with Humana.
Related: Cigna CEO Sued For Efforts To Kill Anthem Deal
Cigna’s Chairman and Chief Executive Officer, David Cordani, expressed confidence in the value of the company’s shares, stating, “We believe Cigna’s shares are significantly undervalued, and repurchases represent a value-enhancing deployment of capital as we work to support high-quality care, improved affordability, and better health outcomes.”
In the wake of the abandoned merger, Cordani also noted that Cigna would explore bolt-on acquisitions aligned with its strategic objectives, as well as “value-enhancing divestitures.” Notably, the company is reportedly considering the sale of its Medicare Advantage business, which manages government health insurance for individuals aged 65 and older. This potential divestiture signifies a departure from Cigna’s previous expansion in this sector.
Humana has refrained from commenting on the matter, while Cigna did not respond to a Reuters request for comment regarding the terminated deal talks. Had the merger been successful, the combined entity would have gained increased scale to compete with prominent U.S. health insurance players such as UnitedHealth Group and CVS Health.
Source: Reuters
Featured News
Electrolux Fined €44.5 Million in French Antitrust Case
Dec 19, 2024 by
CPI
Indian Antitrust Body Raids Alcohol Giants Amid Price Collusion Probe
Dec 19, 2024 by
CPI
Attorneys Seek $525 Million in Fees in NCAA Settlement Case
Dec 19, 2024 by
CPI
Italy’s Competition Watchdog Ends Investigation into Booking.com
Dec 19, 2024 by
CPI
Minnesota Judge Approves $2.4 Million Hormel Settlement in Antitrust Case
Dec 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand